Xin Lang Zheng Quan·2025-12-03 06:34Company Overview - Rongchang Biopharmaceuticals is an innovative biopharmaceutical company established on July 4, 2008, and listed on March 31, 2022, located in Yantai, Shandong, China [2] - The company focuses on the development and commercialization of therapeutic antibody drugs, including antibody-drug conjugates (ADC), antibody fusion proteins, and monoclonal and bispecific antibodies [2] - Main business revenue composition: 99.46% from product sales, 0.38% from material sales, and 0.16% from leasing services [2] Financial Performance - As of September 30, 2025, Rongchang Biopharmaceuticals achieved a revenue of 1.72 billion yuan, representing a year-on-year growth of 42.27% [3] - The net profit attributable to shareholders was -551 million yuan, showing a year-on-year increase of 48.60% [3] Stock Performance - On December 3, Rongchang Biopharmaceuticals' stock price decreased by 2.05%, trading at 91.32 yuan per share, with a total market capitalization of 51.478 billion yuan [1] - The stock has increased by 203.29% year-to-date, but has seen a decline of 1.01% over the last five trading days, 0.74% over the last twenty days, and 1.58% over the last sixty days [1] Shareholder Structure - As of September 30, 2025, the number of shareholders increased by 18.33% to 15,300 [3] - Major shareholders include Hong Kong Central Clearing Limited, holding 8.8418 million shares (a decrease of 510,800 shares), and Wanjiayou Selected, holding 7 million shares (an increase of 1,075,500 shares) [4]